Ocular Therapeutix™: Launching a Bold New Vision in Retina Care
BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL) is making waves in the biopharmaceutical world with its new corporate branding and website, signaling a pivotal shift towards a retina-focused mission. This transformation highlights the company’s dedication to enhancing the experience of individuals affected by retinal diseases.
Vision for Change: Ocular’s Transformation
“Retinal disease, including wet age-related macular degeneration (AMD), is a leading cause of blindness,” shared Pravin U. Dugel, MD, Executive Chairman, President, and CEO of Ocular Therapeutix. “Our objective is to redefine the retina experience to alleviate the heavy burden associated with existing treatments, ultimately preserving long-term vision.” This powerful statement underscores Ocular’s commitment to innovation and patient care.
A New Identity
With its revamped branding, Ocular aims to communicate the significant advancements it’s made in the realm of retinal disease treatment. Their approach, fueled by momentum from the SOL clinical trials, epitomizes a forward-thinking ethos designed to resonate with patients and healthcare providers alike.
Tackling the Challenges of Retinal Disease
Understanding the Burden of Treatment
The statistics are alarming: wet AMD affects 1.8 million people in the U.S., with existing treatment options often demanding up to 12 injections per year. This entanglement creates an immense burden on patients and their caregivers, leading to treatment discontinuation and suboptimal long-term outcomes. In fact, one in four patients develop fibrosis within two years and experience atrophy within five years of starting treatment.
A Game-Changer: AXPAXLI™
Ocular is paving the way for innovative solutions with its investigational therapy, AXPAXLI™ (OTX-TKI). This axitinib hydrogel, administered by intravitreal injection, has the potential to significantly improve durability and long-term outcomes for patients grappling with wet AMD and other retinal diseases.
Experience the Transformation
The new corporate branding is now fully integrated across Ocular’s website, social media, and internal platforms. It will make its debut at the upcoming American Society of Retina Specialists (ASRS) conference, marking a significant chapter in the company’s journey.
Explore the new corporate branding on our website.
About Ocular Therapeutix, Inc.
Ocular Therapeutix is a fully-integrated biopharmaceutical company that is reimagining the experience of retinal diseases. Its flagship product, AXPAXLI™, represents a groundbreaking advancement based on ELUTYX™, a proprietary bioresorbable hydrogel formulation technology. Currently, AXPAXLI is undergoing Phase 3 clinical trials for wet age-related macular degeneration.
Expanding Horizons
In addition to AXPAXLI™, Ocular’s pipeline includes DEXTENZA®, an FDA-approved corticosteroid, and OTX-TIC, a travoprost intracameral hydrogel in Phase 2 trials targeting open-angle glaucoma and ocular hypertension.
Follow the Company via its website, LinkedIn, or X.
The Ocular Logo: A Symbol of Change
The redesigned logo is not merely a visual identity; it is a statement of hope, progress, and accessibility. The circular "O" symbolizes the eye and retina, while the vibrant color palette reflects the richness of human vision. The treatment of the "X" signifies the crossroads of Ocular’s past and its ambitious future.
In Conclusion
Ocular Therapeutix stands at the forefront of redefining retinal care. As they embark on this exciting new chapter, their innovative solutions promise to transform the treatment landscape for countless individuals affected by retinal diseases.
For more insights, check out additional media snippets related to the announcement here.
Media Contact
Bill Slattery
Vice President, Investor Relations
Email: [email protected]
Explore the new vision Ocular is setting forth not just for branding but for the future of retinal treatment.
